Antibodies as Therapeutics
Sponsored by: Thermo Fisher Scientific
Date: 20 October
Time: 3PM London/10AM New York
Ensuring comprehensive antibody characterisation
Antibodies are an attractive choice as therapeutics for a number of reasons such as their antigen specificity, modes of action and their difficulty to be easily copied when coming off patent. Our own immune system has yielded us a powerful weapon which we can utilise to fight disease. However, as we produce these antibody therapeutics in vitro we bypass the immune systems careful in vivo control mechanisms to ensure antibody efficacy and safety. Therefore there are strict requirements to fully and comprehensively characterise antibody therapeutics to certify no changes to the antibody have occurred during its production which could affect its function.
In this webinar, we shall look deeper in to antibodies themselves, how they develop, their structure, functions and modes of action. Why antibodies are such powerful biopharmaceuticals and how they are currently being utilised will also be discussed with relevant examples. This first section of the webinar will end with an overview of potential modifications that can occur to an antibody and the effects they have.
The second part of the webinar will look at the latest chromatography tools and technologies to fully characterise antibodies and ensure their safety, efficacy and consistency with the original antibody. We shall provide practical examples of investigating the antibody's primary structure, aggregation, charge variants and post translational modifications (PTMs) such as glycosylation with new column chemistries and state-of-the-art chromatography instruments.
Register today to gain a thorough oversight in to antibodies, their use as biopharmaceuticals and the tools and technologies that are being used in today's modern analytical laboratory for their characterisation. Discuss the points raised in the webinar with the experts and your peers.
By registering for this webinar you are agreeing to Thermo Fisher Scientific contacting you.
Dr. Timothy Cross,
EMEA Regional Marketing Manager - HPLC, Thermo Fisher Scientific
Dr. Cross has nearly 20 years experience in life sciences, working predominantly with proteins. Dr. Cross currently works with customers on HPLC across a broad spectrum of markets and applications. Prior to Thermo Fisher Scientific, Dr. Cross held a variety of product marketing and marketing management positions in protein technologies at Bio-Rad Laboratories. Previously Dr. Cross was a R&D Scientist within proteomics for Amersham Pharmacia Biotech after completing a PhD. in Immunology from the University of Birmingham, UK.
Dr. Ken Cook,
EU Bio-Separations Support Expert, Thermo Fisher Scientific
Dr. Cook has over 28 years experience supporting liquid and ion chromatography applications with Dionex initially and then Thermo Fisher Scientific. Dr. Cook currently supports customers with bio-separations, focusing on biotherapeutics. Previously Dr. Cook was a lecturer in Biochemistry at the University of Newcastle-Upon-Tyne, UK where he focused on Protein Biochemistry.
Key Learning Objectives
- Science of antibodies; development, structure, function and modes of action
- Why antibodies are such effective and widely used biopharmaceuticals
- Analytical experiments required to fully characterise an antibody
- How to investigate an antibody’s primary structure, aggregation, charge variants and PTMs using modern chromatography techniques
- R&D Managers
- R&D Group Leaders
- Lab Managers
- Principal Investigators
- C Level Management
- Core Facility Directors
- Biopharma Applications
- Biopharma Development and Production
- Product Quality / Quality Control